VYGR Stock Overview
A biotechnology company, focuses on the treatment of gene therapy and neurology diseases.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Voyager Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$8.40 |
| 52 Week High | US$14.07 |
| 52 Week Low | US$6.06 |
| Beta | 0.98 |
| 1 Month Change | 0.48% |
| 3 Month Change | -11.02% |
| 1 Year Change | -26.06% |
| 3 Year Change | 99.52% |
| 5 Year Change | -64.50% |
| Change since IPO | -52.68% |
Recent News & Updates
Recent updates
There's No Escaping Voyager Therapeutics, Inc.'s (NASDAQ:VYGR) Muted Revenues Despite A 28% Share Price Rise
Mar 15
Voyager Therapeutics: A Tortoise With A Shot At Making Gene Therapy Deliver Easier
Mar 08What Does The Future Hold For Voyager Therapeutics, Inc. (NASDAQ:VYGR)? These Analysts Have Been Cutting Their Estimates
Mar 04Voyager Therapeutics, Inc. (NASDAQ:VYGR) Surges 45% Yet Its Low P/S Is No Reason For Excitement
Jan 04Voyager stock rises as Pfizer opts to use AAV capsid for neurologic disease target
Oct 04Voyager Therapeutics hires new finance chief
Sep 07Voyager Therapeutics GAAP EPS of -$0.50 misses by $0.02
Aug 04Looking Back In On Voyager Therapeutics
Jun 08Need To Know: Analysts Just Made A Substantial Cut To Their Voyager Therapeutics, Inc. (NASDAQ:VYGR) Estimates
May 12Voyager Does A Reboot After First Generation Failures
Mar 25Companies Like Voyager Therapeutics (NASDAQ:VYGR) Could Be Quite Risky
Feb 07Voyager Therapeutics: Another Year, Another Deal
Nov 21Some Analysts Just Cut Their Voyager Therapeutics, Inc. (NASDAQ:VYGR) Estimates
Aug 11Newsflash: Voyager Therapeutics, Inc. (NASDAQ:VYGR) Analysts Have Been Trimming Their Revenue Forecasts
Jul 18Shareholder Returns
| VYGR | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 2.1% | -1.2% | -1.2% |
| 1Y | -26.1% | 4.7% | 21.5% |
Return vs Industry: VYGR underperformed the US Biotechs industry which returned 4.7% over the past year.
Return vs Market: VYGR underperformed the US Market which returned 21.5% over the past year.
Price Volatility
| VYGR volatility | |
|---|---|
| VYGR Average Weekly Movement | 9.1% |
| Biotechs Industry Average Movement | 10.7% |
| Market Average Movement | 5.8% |
| 10% most volatile stocks in US Market | 15.6% |
| 10% least volatile stocks in US Market | 2.9% |
Stable Share Price: VYGR's share price has been volatile over the past 3 months.
Volatility Over Time: VYGR's weekly volatility (9%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2013 | 162 | Al Sandrock | www.voyagertherapeutics.com |
Voyager Therapeutics, Inc., a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company’s lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer’s disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer’s disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer’s disease and is in preclinical trial.
Voyager Therapeutics, Inc. Fundamentals Summary
| VYGR fundamental statistics | |
|---|---|
| Market cap | US$442.76m |
| Earnings (TTM) | -US$3.04m |
| Revenue (TTM) | US$119.04m |
3.8x
P/S Ratio-150.1x
P/E RatioIs VYGR overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| VYGR income statement (TTM) | |
|---|---|
| Revenue | US$119.04m |
| Cost of Revenue | US$100.70m |
| Gross Profit | US$18.35m |
| Other Expenses | US$21.39m |
| Earnings | -US$3.04m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.056 |
| Gross Margin | 15.41% |
| Net Profit Margin | -2.56% |
| Debt/Equity Ratio | 0% |
How did VYGR perform over the long term?
See historical performance and comparison